Feline HER2 protein expression levels and gene status in feline mammary carcinoma: Optimization of immunohistochemistry (IHC) and in situ hybridization (ISH) techniques

Microscopy and Microanalysis

Volumn 19, Issue 4, 2013, Pages 876-882

  Soares, Maria ^a   Correia, Jorge ^a   Rodrigues, Pedro ^b   Simões, Margarida ^a   De Matos, Alves ^b,c   Ferreira, Fernando ^a  

^a UNIVERSITY OF LISBON   (Portugal)

^b INSTITUTO SUPERIOR DE CIÊNCIAS DA SAÚDE EGAS MONIZ   (Portugal)

^c HOSPITAL CURRY CABRAL   (Portugal)

Author keywords

Feline human epidermal growth factor receptor 2 gene homolog (fHER2); Feline mammary carcinomas (FMC); Feline topoisomerase 2 alpha gene homolog (fTOP2A); Gene amplification; Immunohistochemistry (IHC); In situ hybridization (ISH); Protein overexpression

Indexed keywords

EID: 84880270936     PISSN: 14319276     EISSN: 14358115     Source Type: Journal    
DOI: 10.1017/S1431927613001529     Document Type: Article

References (31)

1. Bhargava, R., Lal, P. & Chen, B. (2005). HER-2/neu and topoisomerase II a gene amplification and protein expression in invasive breast carcinomas: Chromogenic in situ hybridization and immunohistochemical analyses. Am J Clin Pathol 123(6), 889-895.
2. Bilous, M., Dowsett, M., Hanna, W., Isola, J., Lebeau, A., Moreno, A., Penault-Llorca, F., Ruschoff, J., Tomasic, G. & van De Vijver, M. (2003). Current perspectives on HER2 testing: A review of national testing guidelines. Mod Pathol 16(2), 173-182.
3. Cianciulli, A.M., Botti, C., Coletta, A.M., Buglioni, S., Marzano, R., Benevolo, M., Cione, A. & Mottolese, M. (2002). Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of HER-2 in breast cancer. Cancer Genet Cytogenet 133(1), 66-71.
4. De Maria, R., Olivero, M., Iussich, S., Nakaichi, M., Murata, T., Biolatti, B. & Di Renzo, M.F. (2005). Spontaneous feline mammary carcinoma is a Model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res 65(3), 907-912.
5. Elston, C.W. & Ellis, I.O. (1998). Assessment of histological grade. In Rosen's Breast Pathology, Rosen, P.P. (Ed.), pp. 365- 382. Philadelphia, PA: Lippincott-Raven.
6. Fountzilas, G., Valavanis, C., Kotoula, V., Eleftheraki, A.G., Kalogeras, K.T., Tzaida, O., Batistatou, A., Kronenwett, R., Wirtz, R.M., Bobos, M., Timotheadou, E., Soupos, N., Pentheroudakis, G., Gogas, H., Vlachodimitropoulos, D., Polychronidou, G., Aravantinos, G., Koutras, A., Christodoulou, C., Pectasides, D. & Arapantoni, P. (2012). HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J Transl Med 10(10), 89-110.
7. Gancberg, D., Järvinem, T., Di Leo, A., Rouas, G., Cardoso, F., Paesmans, M., Verhest, A., Piccart, M.J., Isola, J. & Larsimont, D. (2002). Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: An interlaboratory study assessing the reproducibility of HER-2/NEU testing. Breast Cancer Res Treat 74(2), 113-120.
8. McNeill, C.J., Sorenmo, K.U., Shofer, F.S., Gibeon, L., Durham, A.C., Barber, L.G., Baez, J.L. & Overley, B. (2009). Evaluation of adjuvant doxorubicin-based chemotherapy for the treatment of feline mammary carcinoma. J Vet Intern Med 23(1), 123-129.
9. Ménard, S., Tagliabue, E., Campiglio, M. & Pupa, S.M. (2000). Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 182(2), 150-162.
10. Millanta, F., Calandrella, M., Citi, S., Della Santa, D. & Poli, A. (2005). Overexpression of HER-2 in feline invasive mammary carcinomas: An immunohistochemical survey and evaluation of its prognostic potential. Vet Pathol 42, 30-34.
11. Misdorp, W., Else, R.W., Hellmen, E. & Lipscomb, T.P. (1999). Histologic classification of mammary tumors of the dog and the cat. In World Health Organization International Histological Classification of Tumours of Domestic Animals, 2nd ed., Schulman, F.Y. (Ed.), vol. 7, pp. 11-27. Washington, DC: Armed Force Institute of Pathology and World Health Organization.
12. Nassar, A., Cohen, C. & Siddiqui, M. (2009). Estimation of hormone receptor status and HER2 in cytologic cell blocks from breast cancer using the novel rabbit monoclonal antibodies (SP1, SP2, and SP3). Diagn Cytopathol 37(12), 865-870.
13. Oakman, C., Moretti, E., Galardi, F., Santarpia, L. & Di Leo, A. (2009). The role of topoisomerase II alpha and Her-2 in predicting sensitivity to anthracyclines in breast cancer patients. Cancer Treat Rev 35(8), 662-667.
14. O'Malley, F.P., Parkes, R., Latta, E., Tjan, S., Zadro, T., Mueller, R., Arneson, N., Blackstein, M. & Andrulis, I. (2001). Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. Am J Clin Pathol 115(4), 504-511.
15. Ordás, J., Millán, Y., Dios, R., Reymundo, C. & Martin de las Mula, J. (2007). Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: An immunohistochemical and chromogenic in situ hybridization study. BMC Cancer 7, 179.
16. Porrello, A., Cardelli, P. & Spugnini, E.P. (2004). Pet models in cancer research: General principles. J Exp Clin Cancer Res 23(2), 181-193.
17. Porrello, A., Cardelli, P. & Spugnini, E.P. (2006). Oncology of companion animals as a model for humans. An overview of tumor histotypes. J Exp Clin Cancer Res 25(1), 97-105.
18. Rampaul, R.S., Pinder, S.E., Gullick, W.J., Robertson, J.F. & Ellis, I.O. (2002). HER-2 in breast cancer - Methods of detection, clinical significance and future prospects for treatment. Crit Rev Oncol Hematol 43(2), 231-244.
19. Rasotto, R., Caliari, D., Castagnaro, M., Zanetti, R. & Zappulli, V. (2011). An immunohistochemical study of HER-2 expression in feline mammary tumours. J Comp Path 144(2-3), 170-179.
20. Ricardo, S.A., Milanezi, F., Carvalho, S.T., Leitão, D.R. & Schmitt, F.C. (2007). HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol 60(9), 1001-1005.
21. Rosa, F.E., Silveira, C.G., Bérgamo, N.A.,Neto, F.A., Domingues, M.A., Soares, F.A., Caldeira, J.R. & Rogatto, S.R. (2009). Quantitative real-time RT-PCR and chromogenic in situ hybridization: Precise methods to detect HER-2 status in breast carcinoma. BMC Cancer 23(9), 90.
22. Santos, S., Bastos, E., Baptista, C.S., Sá, D., Caloustian, C., Guedes-Pinto, H., Gärtner, F., Gut, I.G. & Chaves, R. (2012). Sequence variants and haplotype analysis of cat ERBB2 gene: A survey on spontaneous cat mammary neoplastic and non-neoplastic lesions. Int J Mol Sci 13(3), 2783-2800.
23. Sidoni, A., Ferri, I., Cavaliere, A., Bellezza, G., Scheibel,M. & Bucciarelli, E. (2006). Detection of HER-2/neu (c-erbB-2) overexpression and amplification in breast carcinomas with ambiguous immunohistochemical results. A further contribution to defining the role of fluorescent in situ hybridization. Anticancer Res 26(3B), 2333-2337.
24. Sorenmo, K.U., Worley, D.R. & Goldschmidt, M.H. (2013). Tumors of the mammary gland. In Small Animal Clinical Oncology,Withrow, S.J., Vail, D.M. & Page, R.L. (Eds.), pp. 547- 552. Philadelphia, PA: Saunders Elsevier.
25. Stebbing, J., Copson, E. & Reilly, S.O. (2000). Herceptin (trastuzamab) in advanced breast cancer. Cancer Treat Rev 26, 287-290.
26. Susini, T., Bussani, C.,Marini, G., Nori, J., Olivieri, S.,Molino, C., Bianchi, S., Vezzosi, V., Paglierani, M., Giachi, M., Borrani, E. & Scarselli, G. (2010). Preoperative assessment of HER-2/neu status in breast carcinoma: The role of quantitative real-time PCR on core-biopsy specimens. Gynecol Oncol 116(2), 234-239.
27. Tanner, M., Isola, J., Wiklund, T., Erikstein, B., Kellokumpu- Lehtinen, P., Malmström, P., Wilking, N., Nilsson, J. & Bergh, J. (2006). Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and doseescalated anthracycline-based adjuvant chemotherapy in HER- 2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24(16), 2428-2436.
28. Vollan, H.K. & Caldas, C. (2011). The breast cancer genome - A key for better oncology. BMC Cancer 30(11), 501.
29. Wang, J., Xu, B., Yuan, P., Zhang, P., Li, Q., Ma, F. & Fan, Y. (2012). TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy. Breast Cancer Res Treat 135(2), 531-537.
30. Wiston, J., Craft, D.M., Scase, T.J. & Bergman, P.J. (2005). Immunohistochemical detection of HER-2/neu expression in spontaneous feline mammary tumours. Vet Comp Oncol 3(1), 8-15.
31. Wolff, A.C., Hammond, M.E., Schwartz, J.N., Hagerty, K.L., Allred, D.C., Cote, R.J., Dowsett, M., Fitzgibbons, P.L., Hanna,W.M., Langer, A., McShane, L.M., Paik, S., Pegram, M.D., Perez, E.A., Press, M.F., Rhodes, A., Sturgeon, C., Taube, S.E., Tubbs, R., Vance, G.H., van de Vijver, M., Wheeler, T.M., Hayes, D.F. & American Society of Clinical Oncology/College of American Pathologists. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131(1), 18-43. Tecnologia